Literature DB >> 9373427

Financial cost of treating out-patients with schizophrenia in Nigeria.

T G Suleiman1, J U Ohaeri, R A Lawal, A Y Haruna, O B Orija.   

Abstract

BACKGROUND: An assessment of the monetary costs of treating a group of Nigerian out-patients with schizophrenia, in comparison with insulin-dependent diabetics, was made.
METHOD: Fifty out-patients with schizophrenia (mean age 42.9) and 40 with diabetes (mean age 41.9), attending government hospitals in Lagos, were assessed at six-monthly intervals, for direct and indirect costs (US$ = 82 naira; minimum monthly wage = 500 naira).
RESULTS: Twenty (40%) of those with schizophrenia and eight (20%) of the diabetics had no income at all. The mean total cost of schizophrenia in six months (2941.4 naira) or US$ 35.9) was significantly less than that of diabetes (11,791 naira or US $143). The cost of antipsychotic drugs accounts for 52.8% of the cost of schizophrenia; insulin injections accounted for 92.8% of the total cost of diabetes. Patients with schizophrenia and their relatives suffered significantly more loss of working days. Cost of illness was not significantly correlated with age and duration of illness.
CONCLUSIONS: Because of drastic currency devaluation, and lack of disability benefits and nursing homes, the findings contrast with Western reports where cost of drugs constitutes 2-5%, and indirect costs constitute over 50% of the total cost of schizophrenia.

Entities:  

Mesh:

Year:  1997        PMID: 9373427     DOI: 10.1192/bjp.171.4.364

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

Review 1.  The state of health economic evaluation research in Nigeria: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 4.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

5.  Cost of ambulatory care of diabetes mellitus: a study from north India.

Authors:  S Grover; A Avasthi; A Bhansali; S Chakrabarti; P Kulhara
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

6.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

Review 7.  The burden of schizophrenia on caregivers: a review.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Healthcare in schizophrenia: effectiveness and progress of a redesigned care network.

Authors:  Dong-Sheng Tzeng; Li-Chiu Lian; Chin-Un Chang; Chun-Yuh Yang; Gian-Tin Lee; Peter Pan; For-Wey Lung
Journal:  BMC Health Serv Res       Date:  2007-08-17       Impact factor: 2.655

9.  The cost of inpatient care of schizophrenia in the Polish and Ukrainian academic centers--Poznan and Lviv.

Authors:  Tomasz Zaprutko; Elżbieta Nowakowska; Krzysztof Kus; Rostyslav Bilobryvka; Lyudmyla Rakhman; Andrzej Pogłodziński
Journal:  Acad Psychiatry       Date:  2014-09-13

10.  Perception of service satisfaction and quality of life of patients living with schizophrenia in Lagos, Nigeria.

Authors:  Taiwo Opekitan Afe; Mashudat Bello-Mojeed; Olawale Ogunsemi
Journal:  J Neurosci Rural Pract       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.